HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology172 papers

Atrial myxoma

Last edited: 4/15/2026

Overview

Atrial myxoma is a rare, primary cardiac tumor originating from the interatrial septum, often presenting with non-specific symptoms that can complicate early diagnosis 1.

Diagnosis

  • Clinical Presentation: May include dyspnea, palpitations, embolic events, and constitutional symptoms 1.
  • Echocardiography: Essential for diagnosis, revealing characteristic mobility and appearance of the mass 1.
  • Cardiac MRI/CT: Provides additional detail for tumor characterization and extent 1.
  • Electrocardiogram (ECG): May show nonspecific changes but can be useful in conjunction with other tests 1.
  • Blood Tests: Elevated biomarkers like BNP can support clinical suspicion 1.
  • Tissue Biopsy: Rarely needed but confirms diagnosis if imaging is inconclusive 1.

    • Management

  • Surgical Excision: First-line treatment, typically via median sternotomy or minimally invasive approach 1.
  • Preoperative Management: Includes stabilization, anticoagulation if indicated, and addressing embolic risk 1.
  • Postoperative Care: Focus on monitoring for complications such as arrhythmias and heart failure 1.
  • Anticoagulation: Post-surgery, to prevent thromboembolic events, duration tailored to patient risk 1.
  • Follow-Up: Regular echocardiograms and clinical evaluations to monitor recurrence and cardiac function 1.

    • Special Populations

  • Pregnancy: Limited data; surgical intervention should be individualized, considering gestational age and maternal condition 1.
  • Elderly: Surgical risk stratification crucial; multidisciplinary approach recommended to balance benefits and risks 1.

    • Key Recommendations

  • Early Echocardiographic Evaluation is critical for diagnosing atrial myxoma due to its characteristic findings 1. (Evidence: Strong)
  • Surgical Excision is the definitive treatment modality for symptomatic or large atrial myxomas 1. (Evidence: Strong)
  • Postoperative Anticoagulation should be considered to mitigate thromboembolic risk, tailored to individual patient factors 1. (Evidence: Moderate)

    • References

    1 Gawthrope IC, Davidson JA. A mysterious case of chest pain. Emergency medicine Australasia : EMA 2005. link

    Original source

    1. [1]
      A mysterious case of chest pain. — Gawthrope IC, Davidson JA Emergency medicine Australasia : EMA (2005)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG